U.S. markets close in 3 hours 34 minutes

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.32+0.24 (+2.64%)
As of 12:25PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close9.08
Open9.12
Bid9.24 x 1200
Ask9.28 x 800
Day's Range8.80 - 9.39
52 Week Range4.45 - 16.60
Volume189,294
Avg. Volume888,729
Market Cap532.559M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-2.10
Earnings DateMar 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer
    Business Wire

    Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer

    Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company’s Chief Medical Officer and a member of the senior leadership team at Precision BioSciences. Dr. List is a world-renowned hematologist with extensive academic and clinical experience in the research and development of hematology and oncology products. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies, including myelodysplastic syndromes, acute leukemia, multiple myeloma, and lymphoma.

  • Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs
    Business Wire

    Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs

    Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it has entered into a Program Purchase Agreement to reacquire all global development and commercialization rights for all CAR T partnered programs covered under its Development and Commercial License Agreement with Servier. This includes its two clinical stage CD19-targeting allogeneic CAR T candidates, PBCAR0191 and PBCAR19B stealth cell, as well as four additional product targets.

  • Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors
    Business Wire

    Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors

    Stanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences.